Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 9%
Hold 64%
Sell 27%
Strong Sell 0%

Bulls say

Moderna is projected to increase product sales from $1.73 billion in 2025 to $2.15 billion in 2026, indicating robust revenue growth potential stemming from its expanding pipeline and product offerings. The company's recent $1.5 billion debt deal enhances its balance sheet, providing additional flexibility to navigate uncertainties and capitalize on future opportunities, while improvements in manufacturing efficiency are expected to help gross margins grow from 30% in 2023 back to 50% in 2025. Furthermore, encouraging clinical trial results in oncology and other therapeutic areas suggest solid prospects for long-term revenue growth, reinforced by valuable partnerships and a diverse portfolio of 35 mRNA development candidates.

Bears say

Moderna's financial outlook is negatively impacted by a significant decline in COVID vaccine sales, which are projected to drop from $18 billion in 2022 to $6.7 billion in 2023, with further reductions anticipated for 2025 due to waning vaccination rates. Additionally, the company faces competitive challenges in the respiratory vaccine market, particularly with its RSV product, mRESVIA, as successful alternatives have already been introduced. Furthermore, uncertainties surrounding its pipeline development outside of respiratory vaccines contribute to a decreased long-term revenue potential, leading to a reduction in the valuation of its COVID-related assets from $11.70 billion to $10.50 billion.

Moderna (MRNA) has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 9% recommend Buy, 64% suggest Holding, 27% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 11 analysts, Moderna (MRNA) has a Hold consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.